Author(s): Bhumi Patel* and Amber Healy
Background: Insulin has been the gold standard treatment for T2DM during pregnancy. However, immerging studies indicate that GLP-1 agonists have shown significant improvement in insulin resistance. Despite promising results, research conducted on pregnant animal models has shown fetal developmental defects associated with GLP-1 agonists. There is scarcity of research conducted on the use of GLP-1 agonists in human pregnancies. This case report describes the exposure to dulaglutide (GLP-1 agonist) during first trimester of pregnancy.
Case: A 41-year-old female with type 2 diabetes mellitus and polycystic ovarian syndrome had been taking dulaglutide until 15 weeks of gestation. She delivered a healthy baby boy via cesarean delivery at 36 weeks’ gestation.
Conclusion: In our case, exposure to dulaglutide during the first trimester showed no significant developmental effects on the baby. However, current research is insufficient to categorize GLP-1 agonists as safe during pregnancy.
View PDF